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urethroplasty for hypospadias: a randomized
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Alejandro González-Ojeda5*Abstract
Background: Urethrocutaneous fistulae (UCFs) represent one of the most frequent causes of morbidity after
urethroplasty. Hypospadias can be repaired using different surgical techniques, but—regardless of technique—the
incidence of UCF ranges between 10% and 40%. Surgical repair of UCF remains the treatment of choice, even if
some patients need further surgery because of recurrences. Cyanoacrylates have been used as skin suture
substitutes, and some evidence suggests a beneficial effect when these adhesives are used as an adjuvant in the
management of UCF. Here we describe the results of management of UCF using 2-octyl cyanoacrylate (OCA)
compared with surgical repair.
Methods: A randomized clinical trial conducted from January 2008 to December 2012 included 42 children with
UCF complications after urethroplasty for hypospadias. Twenty-one children were assigned to receive OCA as
ambulatory patients and 21 were treated surgically. The main outcome variable was closure of the UCF. The
estimated costs of both treatments were also calculated, as were absolute risk reduction (ARR), relative risk
reduction (RRR) and number needed to treat (NNT) to prevent a surgical intervention.
Results: The mean numbers of UCF were 1.3 in the OCA group (n = 28) and 1.1 in the surgical group (n = 25) with
no statistically significant difference. The external orifices measured were 2.96 ± 1.0 mm and 3.8 ± 0.89 mm,
respectively (NS). Sixty per cent of the UCFs treated with cyanoacrylate were completely closed and 68% of the
surgical group healed completely (NS). More than one reoperation to improve complications was needed in the
surgical group (3.5 ± 1.2). The clinical significance of the therapeutic usefulness of OCA was demonstrated by an
ARR of 0.08, RRR of 0.25 and NNT of 12 to avoid further surgical treatment. The total costs of adhesive applications
and reoperations were $US 14,809.00 and $US 158,538.50, respectively.
Conclusions: The results showed a similar success rate for both treatments. However, sealant use should be
considered before surgical treatment because this is a simple outpatient procedure with a reasonable success rate.
Trial registration: ClinicalTrials.gov Identifier: NCT02115191. Date: April 13, 2014.
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Hypospadias is a urological birth defect in which the ur-
ethral meatus is located ventrally anywhere from the tip
of the glans up to the perineum [1]. These defects occur
in 1 in 300 live births (0.3%). Kallen et al. reported a
prevalence of 0.26 cases per 1000 births in Mexico, 2.6
per 1000 births in Hungary and about 5.2 per 1000 births
in Scandinavia, and annually about 6000 neonatal boys in
the US are diagnosed with hypospadias [2]. The anomaly
is detected during examination at birth or prior to the
completion of circumcision [3]. Nine per cent of cases
are associated with inguinal hernia [1,3]. Hypospadias re-
pair was first described in 100–200 years BC; since then,
more than 200 repair techniques have been described
and new techniques are being developed continuously
[3]. Initially, hypospadias surgical repair (HSR) was done
in stages, but since 1950, a one-stage repair has been
considered the treatment of choice [4]. The incidence of
complications varies depending on the severity of the
hypospadias, the patient’s age, previous attempts to repair
and tissue condition. Complications can be immediate,
including wound infection and haematoma. Late compli-
cations include meatal stenosis and retraction, particularly
in the urethra, dehiscence, stricture and diverticulum, and
a urethrocutaneous fistula (UCF). A UCF is very common
and requires reoperation with a 6–12-month interval be-
tween each procedure and a high risk of failure when
simple procedures are used [5-10]. Many cyanoacrylate-
based adhesives have been studied, including isobutyl
cyanoacrylate, isohexyl cyanoacrylate and 2-octyl cyano-
acrylate (OCA). These adhesives have tensile strength,
and bacteriostatic and haemostatic properties. N-Butyl-2-
cyanoacrylate (NBCA) and OCA are the most frequently
used, but the latter has been shown to have better tensile
strength, equivalent to a suture after 7 days [10-13].
NBCA has been used in the urological field for the
embolization of arteriovenous fistulae, in renal segmental
embolization, to seal the vas deferens in sterilization, as a
method of resolving urinary fistulae, and instead of su-
tures during circumcision [12-17]. In 2002, Lapointe
et al. reported a case series of UCF management with
NBCA, which evaluated the efficacy and safety in eight
patients, achieving fistula closure (FC) with adequate
functionality and aesthetics in five (63%). The others had
a remaining fistula and were treated with a second appli-
cation of NBCA combined with bladder drainage, and
subsequently underwent surgical repair that was success-
ful in all of the patients [18]. However, no studies have
been designed to test the utility of using cyanoacrylate
derivatives, especially OCA, as an alternative to trad-
itional surgical treatment of UCF in children. Here we
compared the surgical treatment for closure of UCF sec-
ondary to HSR that is used at our institute with the appli-
cation of OCA, and analysed whether this adhesive couldbe an effective alternative treatment that promotes the
closure of UCF. The aim was to evaluate the effectiveness
of OCA to treat UCF and avoid reoperations.
Methods
From 1 January 2007 to 31 December 2012, a double-
blind randomized clinical trial was conducted in children
with cases of UCF that occurred after hypospadias re-
pair. The patients were assigned to either the control or
the study group. The study group included children with
long-standing UCF that appeared at least 6 months after
the initial intervention. After preparation of the fistula
area, multiple layers of OCA were applied, attaching the
edges of the orifice. The same procedure was repeated
three times and children were followed for at least
12 months after treatment. The control group included
children with long-standing UCF that occurred at least
6 months after the initial intervention. Patients were
scheduled for surgical treatment and followed for at least
6 months after surgery. If UCF recurred, a new interven-
tion was proposed. The sample size was determined
based on a prevalence of the complication (UCF) of 25%
in the surgery group and 75% in those patients treated
without any adjuvant or adhesive treatment and consid-
ered as having attained spontaneous closure (25%), given
a confidence level of 95% and a power of 0.20, which
resulted in a minimum sample size of 18 patients per
group. The inclusion criteria included children younger
than 5 years old with at least one postoperative UCF
with an external orifice less than 5 mm in diameter at
the distal, proximal or medial penis, and whose parents
or guardians accepted inclusion in the study by signing
the informed consent form. Patients were excluded for
the following reasons: if the external orifice was more
than 5 mm in diameter; if there were iatrogenic or trau-
matic fistulae; the presence of obstruction distal to the
fistula; if there was necrotic tissue or active infection at
the surgical site; if they had chronic diseases such as dia-
betes mellitus, renal or hepatic insufficiency, malignancy
of any type; or the use of steroid and/or immunosup-
pressive therapy of any kind. The independent variables
were the application of OCA to the UCF orifice or surgi-
cal treatment of UCF, and the main outcome variable
was FC without recurrence within at least 12 months of
follow-up. As confounding variables, we considered the
children’s age, the fistulous orifice diameter, and the type
of initial surgical procedure to which all were submitted.
Procedure
Assignment of patients to groups was performed using a
sealed envelope chosen randomly by the father, mother
or guardians. These were prepared by a third person not
involved in the protocol and kept in an agreed location.
Follow-up staff and data analysts were kept blinded to
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response and oedema, patients in the study group were
instructed to apply triamcinolone cream to the fistula
four times a day for 3 days. Once this treatment was
completed, the patient attended our clinic as an out-
patient to undergo treatment, after sedation with mid-
azolam (0.5 mg/kg orally) and Foley catheterization with
a 10 Fr gauge siliconized catheter, with the balloon in-
flated with 1.5 ml of water to prevent bladder spasms.
After preparation of the fistula area with a gentle scarifi-
cation of the edges with a 27-g needle and cotton swabs
to produce slight bleeding, we applied OCA adhesive
using Adson dissecting forceps to approximate the edges
of the UCF and then applied several thin layers of OCA.
The urethral catheter was left in place for 5 days. At the
end of this time, we evaluated any closure or persistence
of the UCF. If the UCF persisted, the OCA adhesive was
applied twice more at intervals of 30 days following the
same protocol, before the medical procedure was deemed
to have failed. Patients in the control group waited
6 months to be treated surgically. The reoperation con-
sisted of mobilizing dartos flaps and closing the defect in
layers with absorbable sutures. Urinary bladder drainage
was provided with a 10 Fr silicone Foley catheter, with the
balloon inflated with 1.5 ml of water to prevent bladder
spasm. The follow-up time was 12 months for each group.
Statistical analysis
The descriptive phase of the analysis included the pres-
entation of data as raw proportions, and means and
standard deviations. Fisher’s exact test or the χ² test
were used to compare qualitative variables. The distribu-
tion of the quan- of the quantitative variables was ana-
lysed with the Kolmogorov Smirnov test to determine
whether they showed a normal distribution as required
for the use of Student’s t test. Microsoft Excel 2007
(Redmond, WA, USA) and SPSS for Windows (version
17; SPSS Inc., Chicago, USA) were used for data process-
ing and statistical analysis. For all variables, a value of
P <0.05 was considered statistically significant. To estab-
lish the clinical significance of the results, we determined
the absolute risk reduction (ARR), relative risk reduction
(RRR) and number needed to treat (NNT) to avoid
reoperation.
Ethical considerations
This study was conducted according to the Declaration
of Helsinki (2008) and Mexican Health Guidelines. The
protocol was approved by the Ethics Committee of the
Children’s Hospital of the Western National Medical
Center (code 2003-1202-036). Also, the protocol was
registered at National Clinical Trials number 02115191.
Full written informed consent was obtained from all
patients’ carers before their inclusion in the study.Results
From 1 January 2007 to 31 December 2012, 42 children
who had one or more UCFs following surgical treatment
for hypospadias were enrolled (Figure 1). Twenty-one
children were assigned to group 1 (application of OCA)
and 21 were assigned to group 2 (surgical closure). The
average age of group 1 was 28.6 ± 24.5 months (range 10–
76 months) and that of group 2 was 35.4 ± 17.6 months
(range 9–82 months; NS). Based on the Barcat classifi-
cation of hypospadias, group 1 included nine patients
(43%) with proximal, seven (33%) with medial and five
(24%) with distal hypospadias; group 2 included 10 pa-
tients (48%) with proximal, six (29%) with medial and five
(24%) with distal hypospadias. There was no significant
difference between the groups in the location of the
hypospadias. Congenital malformations were present in
nine patients (43%) in group 1 and in 13 patients (62%)
in group 2; this was not significantly different as de-
scribed in Table 1. In group 1, the average number of
UCFs per patient was 1.3 (range 1–4), while for group 2
it was 1.1 (range 1–2; NS). No significant difference was
found between groups in the size of the UCFs; the aver-
age size in group 1 was 2.96 ± 1.0 mm compared with
3.82 ± 0.89 mm in group 2 (NS). The characteristics of
both groups related to the surgical technique used for the
initial cure of hypospadias prior to inclusion in this study
are presented in Table 2. In group 1, 17/28 successful
UCF closures were achieved without recurrence with an
average of 2.5 applications of 1 ml of OCA (range 1–3),
while in group 2, 17/25 UCF closures were achieved with
an average of 3.2 ± 1.2 surgeries. There was no significant
difference between the groups in the rate of resolution of
the UCFs (Table 3). However, the clinical significance of
the therapeutic usefulness of OCA was demonstrated by
an ARR of 0.08 (8%), RRR of 0.25 (25%) and an NNT of
12 to avoid surgical treatment. Although it was not an
objective of this study to perform a cost–benefit analysis,
we found that for medical treatment, the cost of each ad-
hesive application was 3,526 Mexican pesos (equivalent
to $US 282), while the cost of surgery and a 1-day hospital
stay was 28,668 Mexican pesos ($US 2,294). The total cost
of treating each group, considering the total number of
applications of OCA and reoperations to achieve a suc-
cessful closure of the UCF, was 185,115 Mexican pesos
($US 14,809) for group 1 and 1,931,731.20 Mexican pesos
($US 158,538.50) for group 2. Reported complications
resulting from the application of the OCA adhesive were
minor: nine patients reported a sensation of local tem-
perature increase (42.8%), and 2 days of transient dysuria
was reported in one patient (4.7%).
Discussion
The management of UCF resulting from surgery to cure
hypospadias remains a problem, as the rate of this




randomization 21 were assigned to 
the OCA application 
group 
21 completed the follow-up and were 
included in the intention to treat 
analysis  
21 were assigned to 
surgical fistula 
closure group 
21 completed the follow-up and were 
included in the intention to treat 
analysis  
13 did not provide 
consent
Figure 1 Enrolment and outcomes.
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35% [6-9]. In a cohort study conducted at our hospital,
the incidence of UCF was 41% in children undergoing
surgical repair of hypospadias. The incidence was not-
ably different from that (10%) observed in patients
undergoing similar surgical procedures that included the
application of fibrin glue with or without reinforcing su-
ture lines at the surgical site [19]. In contrast, Barbagli
et al. evaluated 1176 patients undergoing treatment for
hypospadias with different techniques. They observed
complications in 64.6% of their patients, of which UCF
was the most common (20.7%). They used different ap-







Age (months) 28.6 ± 24.5 35.4 ± 17.6 NS*
Barcat classification NS**
Proximal 9 (43%) 10 (48%)
Medial 7 (33%) 6 (29%)
Distal 5 (24%) 5 (24%)
Number of fistulae 1.3 (1–4) 1.1 (1–2) NS*
Diameter (mm) 2.96 ± 1.0 3.82 ± 0.89 NS*









NS, not significant; *Student’s t test; **χ2 test.reoperations was 2–23 per patient (mean 5) [6]. The sur-
gical technique used to repair hypospadias has a definite
impact on the development of UCF. Thus, the incidence
of UCFs with an advanced technique of urethroplasty
was 0.5–10%, in the graft wrap technique it was 2.2–
35%, for the distal urethral hypospadias advancement it
was 1–16.7% and in tubulization with pedunculated is-
land repair it was 4–33% [20-24]. Smith reported that
the incidence decreased to less than 3% with the two-
stage technique of repair [25], and Greenfield et al. re-
duced the incidence to less than 2.5% using the modified
Belt–Fuqua two-stage technique in cases of severe hypo-
spadias [26]. However, reports persist of adverse out-
comes after initial surgery for hypospadias corrections,
with a prevalence of 55–77% for UCF [27,28]. Cyanoacry-
lates are monomers that polymerize quickly when hydro-
gen ions are present, creating a solidified acrylic resin in
less than a minute. They exist in two forms: as short-
chain cyanoacrylates including methyl-2-cyanoacrylate or
ethyl-2-cyanoacrylate, which are rarely used because of
their rapid degradation to formaldehyde, a powerful tis-
sue toxin; and as long-chain cyanoacrylates includingTable 2 Surgical technique employed to treat
hypospadias







MAGPI, meatal advancement and glanuloplasty technique.






Number of UCFs 28 25 NS
Interventions to
close UCF
2.5 ± 0.5* 3.2 ± 1.2** NS
Successful
UCF closure
17/28 (60%) 17/25 (68%) NS, 0.86
(0.52–1.44)***
NS, not significant. *Number of applications of 2-octyl cyanoacrylate.
**Number of surgical interventions. ***Relative risk (95% confidence interval).
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lower toxicity, and so are widely used in the repair of fa-
cial skin wounds [29-31]. Bardari et al. [32] noted that
the use of the cyanoacrylate family of adhesives is an ex-
cellent option for the management of urinary fistulae be-
fore deciding on surgical treatment, because of its safety
and effectiveness with only minor risks. In a small study,
Lapointe et al. [18] established the utility of using NBCA
to heal UCF, with success in five of eight patients (63%),
and alluded to a savings in resources with the use of the
cyanoacrylate in contrast to the higher cost of surgery. In
2011, Prestipino et al. [33] reported a small clinical trial
using NBCA, including six children with early deve-
lopment of UCF (<72 h after urinary catheter removal
following HSR) and seven children with late UCF devel-
opment (up to 6 months after HSR), noting successful
FC in seven of the 13 children (54%). Based on this, even
though they concluded that surgical repair of UCF is the
gold standard, they emphasized the ease of adhesive ap-
plication even without sedation, which could be repeated
several times as needed: the principal advantage was in-
creased tensile strength. They also proposed a clinical
trial to confirm whether surgical treatment should re-
main the gold standard. Tan et al. [34] reported a retro-
spective case series, including 37 children with UCF after
HSR in whom at least one attempt at repair had been
made, who underwent surgical treatment according to
the location of the fistula. Tubulized urethroplasty was
performed in eight patients; 17 of those with proximal
hypospadias and cord presence needed a phased repair
by initial cord fixation followed by urethroplasty; and 12
patients with multiple UCFs who, despite previous repair
attempts, underwent urethroplasty, urethral diverticulum
resection and tubulization as required on an individual
basis. All patients had suture line reinforcement with
OCA. The study found UCF recurrence in only four
(11%) of the patients. Based on the waterproofing and
moisture-resistance properties of the cyanoacrylate adhe-
sives, Hosseini et al. [35] undertook a case–control study
in 61 children with a mean age of 13.5 months who
underwent HSR using different techniques. Patients were
divided into two groups: 41 children in whom conven-
tional dressings were placed on the surgical site (controlgroup) against 20 children in whom the suture lines were
reinforced with NBCA+OCA (study group). The authors
observed that the prevalence of bruising and infection
was 10% in the study group and 25% in the control
group. They emphasized the beneficial effects of decreas-
ing the incidence of haematomas and infections from ex-
posure to urine and faeces in children treated with the
waterproof adhesive. Our study here was robust statisti-
cally because of the number of patients included and the
randomization procedure for the application or non-
application of OCA. We demonstrated that UCF closure
was achieved in 60% of our adhesive-treated UCF pa-
tients and in 68% of those treated surgically. Although
the difference between groups in the successful UCF
closure rate was not statistically significant, these results
indicate clearly that the procedure should be included in
the postoperative management of UCF and, as suggested
by Lapointe et al. [18], Prestipino et al. [33], Tan et al.
[34] and Hosseini et al. [35], should be regarded as an
alternative to surgery for preventing or treating UCF.
These observations support the results of simpler studies,
such as those reported by Tsur et al. [36] and Castañón
García-Aliz et al. [37]. It is important to note that the
cyanoacrylate closure manoeuvre can be attempted on
numerous occasions and, as suggested by Prestipino et al.
[33], even in the absence of sedation. In contrast, our re-
sults with the gold standard surgical treatment showed
that success was achieved only after an average of three
reoperations. The studies reported in the literature suggest
that the occurrence of major adverse side effects that re-
quire removal of different types of adhesive (NBCA, OCA
or NBCA plus OCA) are rare. Our evaluation showed that
the most common side effect with OCA was a feeling of
increased temperature without burning or necrosis.Conclusions
These adhesive products may be considered an excellent
alternative medical treatment that can be performed on an
outpatient basis without sedation or anaesthesia. It causes
less psychological stress or anxiety than the surgical man-
agement of children, which requires hospitalization and
has some inherent risks. Other advantages are that the
use of adhesives does not contra-indicate subsequent
surgical procedures in the event of a failure of UCF reso-
lution with this simple therapeutic manoeuvre. The eco-
nomic benefit of using adhesives to treat this complication
appears to be significant, as it is the least expensive and
most repeatable medical procedure without the risks of
surgery. However, this assessment must be confirmed
with an appropriate costing study on more cases.
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